- Knowledge center
Servier is a French pharmaceutical group and key-player in oncology. For their LONSURF pipeline, they have initiated a phase I dose escalation study with the exploratory objective to evaluate biomarkers that may predict response and resistance to LONSURF in combination therapy. To this end, Biogazelle used digital PCR to quantify cancer gene mutations in patient plasma samples.
"We are very satisfied with how this project is managed at Biogazelle. The project managers at Biogazelle again show off their high level of expertise and open communication. As this project is running well, we are keen on working with Biogazelle on future clinical projects"
Dr Brian Lockhart, Director of Biotechnology, Servier, France